FDA Modernizes Drug Quality Assessment with KASA

May 6, 2024
|

The FDA is transforming drug quality assessments with the new Knowledge-aided Assessment & Structured Application (KASA) system.

This innovative platform captures knowledge throughout a product’s lifecycle, utilizes algorithms for risk assessment and supports computer-aided analysis, promoting efficiency and clarity in the FDA drug approval process.

Key Benefits of KASA:

  • Enhances knowledge management and decision-making.
  • Streamlines risk assessment and control for products and manufacturing facilities.
  • Encourages the use of digital technology to improve regulatory submissions.

 

ASPHALION CAN HELP WITH:

  • Compilation of product quality data in a structured format.
  • Support with M4Q guidelines and recommendations when preparing the quality section of the dossier.
  • Support with electronic data standards.
  • Ensuring
  • Updating change management

 

Contact us! [email protected]

Search News & Events

  • Filter by category

Share

Related news and events

EVENT | DIA Europe

DIA Europe 2025 will focus on sustainability, innovation and collaboration – three key pillars for shaping the future of healthcare. From the environmental impact of pharmaceuticals and of the drug development lifecycle to sustainable partnerships and sustainable healthcare systems, DIA Europe 2025 will be the prime opportunity to discuss how collaboration and innovation can support sustainability in healthcare and each stakeholder’s role in making it happen.

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting